Acadia, page-1503

Some points of interest from Acadia’s R &D Day presentation:

• Slide 5 – Note that 2591 in Rett/Fragile X is categorized as “core pipeline”.
• Slide 6 – Interesting internal assessment of potential peak sales of US$1.5 -2 bn for Nuplazid and DayBue combined, suggesting the potential for current product annual sales to grow by another US$500m to $1 bn. Annual sales estimates for Nuplazid, as it enters its tenth year of sales, are US$650-690 m. If Nuplazid sales were to increase by, say, a further 50% to reach peak sales, that would suggest potential peak sales for DayBue of US$500 m - $1 bn.
• Slide 87 – While the 3 graphs shown aren’t comparing apples with apples, a clear trend of continuing improvement with long-term use of DayBue is evident.
• Slide 90 – Again the benefits of long-term use of DayBue are clear. While 56.9% of patients had demonstrated improvement (using the clinician-assessed CGI-1) at the end of the 3 month Lavender trial, 77.6% had shown improvement at 6 months and 98.3% at 12 months.
• Slide 91 - While improvement is seen in both paediatric and adult patients, slightly more improvement is seen in the younger patients.
• Slide 94 – 2591 is mentioned as a "next-generation approach to the treatment of Rett syndrome."
• Slide 102 – Mmm! According to this slide, Acadia spent just US$120m on Phase 3 and related costs for the development of DayBue. Yet Acadia’s external provider R & D costs for trofinetide, as recorded in the company’s SEC filings, totalled US$195m from signing 2018 until the end of Q3 2023. That figure doesn’t include internal R & D costs, any upfront or milestone payments or any commercialisation costs for the drug.

https://ir.acadia.com/events-and-presentations